Jeremy Preston appointed to Sequins board, and as Chief Commercial Officer

Sequins, an Australian and US startup commercializing the next generation of spike-in internal standards molecular controls, is excited to announce the appointment of Jeremy Preston as both Chief Commercial Officer and as a board member.

As a veteran industry executive, Jeremy brings c-level experience to Sequins from a career driving growth in flagship and breakthrough genomics products at illumina, where he held senior leadership roles across marketing, sales and product, and more recently as CEO of CS Genetics, the single-cell platform company.

Jeremy has been instrumental in bringing Sequins first products to market, including Whole Genome, Metagenomics, and the Sequins On-demand platform, establishing partnerships with leaders in industry, academia and core facilities.

As CCO, Jeremy will be leading the growth of Sequins commercial team and bringing a wealth of strategic expertise to strike further partnerships with early customers and collaborators as the company expands access to internal spike-in standards as a new gold-standard for error measurement and control across genomics applications.